Skip to main content
main-content

Multiple sclerosis

Multiple sclerosis

23-05-2016 | Multiple sclerosis | News | Article

Mitoxantrone for MS linked to colorectal cancer risk

Treatment with mitoxantrone for multiple sclerosis carries only a mildly increased risk of malignancy overall, but the risk of colorectal cancer and leukaemia is heightened, researchers have found.

13-05-2016 | Multiple sclerosis | News | Article

On-treatment relapse drives disability accrual in MS patients

Frequent relapse activity appears to be a key driver of disability accrual in patients with relapse-onset multiple sclerosis, indicates a study of patients receiving first-line injectable disease-modifying treatment.

04-05-2016 | Multiple sclerosis | News | Article

Real risk of rebound syndrome following fingolimod cessation for MS

Rebound syndrome following cessation of fingolimod for multiple sclerosis occurs at a clinically relevant rate, shows research, prompting the need for further study on how best to sequence and discontinue such drugs.

Man_walking stick

25-04-2016 | Multiple sclerosis | News | Article

Rituximab outperforms fingolimod after natalizumab switch

Rituximab is more effective and better tolerated than fingolimod for patients with multiple sclerosis needing to switch from natalizumab due to JC-virus antibody positivity, research suggests.

Retina

23-03-2016 | Multiple sclerosis | News | Article

Retinal thickness points to disability worsening in MS patients

The thickness of the peripapillary retinal nerve fibre layer may help to predict worsening disability in patients with multiple sclerosis, optical coherence tomography findings indicate.

10-03-2016 | Multiple sclerosis | News | Article

Excess comorbidity flagged in MS patients

Patients with multiple sclerosis have more comorbidities than would be expected for their age, even at the time of diagnosis, say researchers.

white_pills_tablets

08-03-2016 | Multiple sclerosis | News | Article

Metabolic syndrome treatment benefits MS patients

Oral antidiabetic medications have beneficial anti-inflammatory effects in patients with multiple sclerosis and metabolic syndrome, providing support for a link between metabolism and autoimmunity, researchers report.

07-03-2016 | Multiple sclerosis | News | Article

Vitamin D deficiency during pregnancy linked to MS risk

Children born to mothers deficient in vitamin D during early pregnancy have an increased risk of developing multiple sclerosis as adults, researchers report.

17-02-2016 | Multiple sclerosis | News | Article

Promising phase II results for ozanimod in MS

The selective sphingosine 1-phosphate receptor inhibitor ozanimod significantly reduces lesion activity in patients with relapsing–remitting multiple sclerosis, shows a phase II study published in The Lancet Neurology.

03-02-2016 | Multiple sclerosis | News | Article

Natalizumab shows relapse prevention benefits over fingolimod in MS

Natalizumab may be superior to fingolimod for preventing relapses during the first year of treatment in patients with relapsing–remitting multiple sclerosis, observational study findings show.

28-01-2016 | Multiple sclerosis | News | Article

Fingolimod trial INFORMS primary progressive MS strategy

Fingolimod is unable to slow disability progression or brain volume loss in patients with primary progressive multiple sclerosis, show the findings of the INFORMS study.

27-01-2016 | Multiple sclerosis | News | Article

Neuroprotection powers for phenytoin in acute optic neuritis

Selective sodium channel blockade with the anti-epileptic drug phenytoin protects against acute demyelinating optic neuritis, researchers report.

02-12-2015 | Multiple sclerosis | News | Article

Phase II study hints at oestriol effect in multiple sclerosis

Oestriol, given in combination with glatiramer acetate, may reduce the risk of relapse in women with relapsing–remitting multiple sclerosis, suggest findings from a phase II trial.

02-11-2015 | Multiple sclerosis | News | Article

General psychiatric support warranted in MS patients

Multiple sclerosis has a nonspecific effect on psychiatric morbidity, increasing the risk of all psychiatric disorders, shows a large population-based study.

21-10-2015 | Multiple sclerosis | News | Article

Culprit B cells identified for MS

Researchers have identified a subset of B cells that contributes to multiple sclerosis pathology independently of antibody production.

14-10-2015 | Multiple sclerosis | News | Article

GATE opens for generic equivalent to glatiramer acetate in MS

Findings from the GATE study have shown equivalent efficacy and tolerability for a generic version of glatiramer acetate to that of the original brand version in the treatment of relapsing–remitting multiple sclerosis.

12-10-2015 | Multiple sclerosis | News | Article

Ocrelizumab succeeds in primary progressive MS

Top-line findings from the ORATORIO study indicate that ocrelizumab reduces the rate of disability progression in patients with primary progressive multiple sclerosis.

Young woman_arm injection

07-10-2015 | Multiple sclerosis | News | Article

Daclizumab HYP superior to interferon in relapsing–remitting MS

The DECIDE study shows that 4-weekly daclizumab high-yield process reduces disease activity in patients with relapsing–remitting multiple sclerosis more effectively than weekly interferon beta-1a, albeit at the cost of more adverse effects.

22-09-2015 | Multiple sclerosis | News | Article

Progression confirmation period too short to define disability persistence in MS

Researchers recommend extending the minimum timeframe for confirming disability progression in multiple sclerosis from 3–6 months to 12 or 24 months to better distinguish true irreversible disability from relapse-associated transient disability.

quitting smoking

11-09-2015 | Multiple sclerosis | News | Article

Quitting smoking may delay secondary progressive MS onset

Patients who are smokers when diagnosed with relapsing–remitting multiple sclerosis may be able to delay the time to onset of progressive disease by quitting smoking, a study suggests.